Ovarian hyperstimulation syndrome (OHSS) explained: why it can happen during IVF stimulation, when symptoms start, which warning signs mean calling the clinic, and how clinics reduce the risk

What is ovarian hyperstimulation syndrome (OHSS)?

Ovarian hyperstimulation syndrome, shortened to OHSS, is a complication of fertility treatment rather than a condition anyone starts out with. Cleveland Clinic explains that OHSS happens when the ovaries swell and leak fluid into the abdomen, and describes it as a complication of fertility treatments, particularly IVF. The American Society for Reproductive Medicine's ReproductiveFacts.org fact sheet defines it as an excessive response to taking the medicines used to make eggs grow, especially injectable gonadotropins, and notes that it can rarely result from other medications such as clomiphene citrate. The UK's Royal College of Obstetricians and Gynaecologists, RCOG, calls it a potentially serious complication of fertility treatment, particularly of in vitro fertilisation. University of Washington Medicine fills in the physical picture in its patient handout: hormone changes from fertility medicines can make blood vessels leaky, so fluid moves out into places it should not be, like the belly or chest, which can cause swelling and other problems and can make the blood thicker, or more concentrated. Severity is graded. ASRM explains that OHSS is classified as mild, moderate, or severe, that the ovaries are enlarged in all cases, and that ovary size is a marker of the degree of OHSS, measured with ultrasound when symptoms are present. Where an individual situation sits on that scale is never a self-diagnosis; it is an assessment for the treating clinic and a licensed physician.

Why can OHSS happen during IVF stimulation?

The honest starting point is that the mechanism is not fully mapped. University of Washington Medicine states plainly that the causes of OHSS are not fully understood, and that it is believed to happen because of the hormones from the ovaries and the fertility medicines. What the sources agree on is the chain of events. ASRM explains that women with OHSS have a large number of growing follicles along with high estradiol levels, and that this leads to fluid leaking into the abdomen, which can cause bloating, nausea, and swelling. Fertility Network UK, a patient charity, describes the same picture simply: too many eggs develop in the ovaries, which then become swollen and painful. The trigger injection plays a particular role. Cleveland Clinic points to HCG, human chorionic gonadotropin, stimulating the ovaries, with the blood vessels around the ovaries leaking fluid, and WebMD explains that fertility treatments, especially those involving injections of HCG, can overstimulate the ovaries. University of Washington Medicine adds that OHSS may get worse after the ovulation trigger shot, because this shot causes follicles to mature and prepare eggs for release. WebMD also notes that oral fertility medications do not usually cause OHSS, which is why the syndrome is discussed mainly around injectable stimulation for IVF. How a specific protocol balances stimulation against this risk is a design question for the treating clinic and a licensed physician.

Who is more likely to develop OHSS?

Several sources publish overlapping risk factor lists. Cleveland Clinic names a diagnosis of polycystic ovary syndrome, PCOS, a previous episode of OHSS, a large number of follicles or high estrogen levels during stimulation, high doses of HCG, a fresh rather than frozen embryo transfer, and possibly being younger than thirty or below average weight. University of Washington Medicine's list is similar from the monitoring side: very high estradiol levels, multiple growing follicles, many eggs retrieved, a condition like polycystic ovarian syndrome, and high levels of anti-Mullerian hormone, AMH. RCOG adds that the risk is higher for women who have polycystic ovaries, are under thirty years old, have had OHSS previously, or become pregnant in the same IVF cycle, and it notes that mild OHSS is common in women having IVF treatment while moderate or severe OHSS affects far fewer. ASRM's fact sheet puts the frequency of the mild form concretely, stating that one out of three women has symptoms of mild OHSS during controlled ovarian stimulation for IVF. Two practical points follow. First, several of these factors, such as follicle number, estradiol, and AMH, are exactly what clinics measure during monitoring, so risk is reassessed as a cycle unfolds. Second, having a risk factor is not a prediction. What an individual risk profile means for protocol, trigger, and transfer decisions belongs with the treating clinic and a licensed physician.

When do OHSS symptoms usually start?

Timing is one of the most searched questions, and the sources give consistent answers. Cleveland Clinic states that symptoms often begin within a week after using medication to stimulate ovulation, though it can take two weeks. ASRM says OHSS symptoms usually appear a few days after ovulation. Fertility Network UK places it in everyday treatment terms, noting that OHSS generally develops in the week after egg collection. University of Washington Medicine adds that OHSS may get worse after the ovulation trigger shot, which is why some monitoring routines begin at the trigger rather than at retrieval. Duration is equally consistent across the sources, with one important exception. RCOG tells patients that most symptoms should resolve in seven to ten days. ASRM says symptoms usually resolve within two weeks unless pregnancy occurs, and Cleveland Clinic and University of Washington Medicine give the same one-to-two-week picture. The exception is pregnancy. ASRM explains that pregnant women often continue to have symptoms for two to three weeks or more after a positive pregnancy test, that the symptoms gradually go away, and that the rest of the pregnancy is not affected. RCOG likewise notes that if pregnancy occurs, OHSS can get worse and last up to a few weeks or longer. Anyone whose symptoms arrive outside these windows, worsen instead of easing, or simply persist should not try to interpret the calendar alone; that interpretation belongs to the treating clinic and a licensed physician.

What are the symptoms of mild and moderate OHSS?

Some bloating and discomfort after egg retrieval is common, which is exactly what makes OHSS confusing, because its mild form looks like an exaggeration of the expected. ASRM describes mild OHSS as mild abdominal bloating, nausea, and weight gain due to fluid, and notes that women with moderate OHSS typically have more of these same symptoms. University of Washington Medicine lists the most common first symptoms of mild to moderate OHSS as belly bloating and discomfort, weight gain of up to ten to fifteen pounds of fluid, nausea, constipation, and a sense of fullness in the pelvic area caused by the enlarged ovaries. Cleveland Clinic's mild to moderate list is abdominal pain, bloating, weight gain exceeding two pounds daily, and nausea. WebMD adds vomiting, diarrhea, and ovary tenderness to the milder picture. RCOG draws the line between grades in a way patients can use: mild OHSS means mild abdominal swelling, discomfort, and nausea, while moderate OHSS means the same symptoms with worse swelling because fluid is building up in the abdomen, which can cause abdominal pain and vomiting. The practical lesson of these lists is that trends matter as much as single symptoms, which is why University of Washington Medicine asks at-risk patients to weigh themselves every morning and watch their urine. Whether a given day's bloating is routine recovery or early OHSS is not a call to make alone at home; it is a call for the treating clinic and a licensed physician.

Which warning signs mean you should contact the clinic right away?

Every source draws a bright line around symptoms that should prompt immediate contact. ASRM's fact sheet says women should notify their doctor when they have difficulty breathing, continued vomiting or nausea, difficulty tolerating fluids, abdominal swelling, decreased urination, weight gain of over three pounds in two days, sudden onset of abdominal pain, or other symptoms such as facial numbness, weakness, or lower extremity swelling or redness, and it urges seeing a doctor familiar with assisted reproduction as soon as symptoms appear. Cleveland Clinic singles out a painful, swollen leg or chest pain as reasons to contact a provider immediately. University of Washington Medicine gives its patients concrete thresholds: call the clinic for weight gain of more than two pounds a day, less than a cup of urine in eight hours, or dark-looking urine, and call right away for nausea, vomiting, or severe belly pain. WebMD's list includes difficulty breathing, severe abdominal pain, inability to keep down food or liquids, weight gain exceeding two pounds daily, lightheadedness, dizziness, and infrequent urination. RCOG advises calling for medical help particularly if pain is not getting better, or with vomiting, urinary problems, chest pain, or difficulty breathing, and Fertility Network UK tells anyone with symptoms after any ovarian stimulation to contact their fertility clinic immediately. When in doubt, the sources all point the same way: raise it without delay with the treating clinic and a licensed physician.

How do clinics reduce the risk of OHSS?

Risk reduction starts before the first injection and continues after retrieval. Cleveland Clinic lists the main levers: reducing the medication dosage, avoiding HCG trigger shots, changing medications, or freezing embryos so transfer happens later. ASRM explains several of these in more detail: reducing the dose of ovarian stimulation medications may reduce the risk, using a medicine called leuprolide instead of HCG to prepare the eggs for release can prevent OHSS, a medicine called cabergoline can reduce the fluid accumulation, and some high-risk patients are given extra IV fluids at the time of egg retrieval. Because pregnancy can make OHSS worse or last longer, ASRM notes that freezing eggs or embryos for transfer at a later time can help OHSS resolve more quickly and keep it from progressing, which also explains why Cleveland Clinic lists a fresh rather than frozen embryo transfer among the risk factors. University of Washington Medicine says severe OHSS can usually be avoided with close monitoring and describes the same toolkit: freezing all embryos for a later frozen embryo transfer cycle, a Lupron trigger, avoiding or reducing HCG, cabergoline during the trigger and after retrieval, letrozole after retrieval, and, if tests show the risk is very high, cancelling the cycle. It also enlists the patient, asking those at risk to drink electrolyte-rich fluids, weigh themselves each morning, check their urine, and report daily. Which measures fit a particular cycle is a protocol decision that rests with the treating clinic and a licensed physician.

How is OHSS managed if it develops?

If OHSS develops, management is mostly supportive. RCOG is frank that no treatment can reverse OHSS and that it will usually get better with time, and University of Washington Medicine says the same thing from the clinic side: treatments focus on keeping the patient comfortable until symptoms improve. ASRM describes typical outpatient care as office visits with ultrasound exams to measure the ovaries and the fluid in the abdomen, blood tests, decreased activity, drinking plenty of electrolyte-rich fluids, medicines for nausea, and, when fluid collects, drainage with a syringe, called paracentesis, which provides significant relief in most cases; it adds that cabergoline can reduce the fluid accumulation and that hospitalization is rarely needed. ASRM also cautions that a standard pelvic exam is not generally recommended, because the enlarged ovaries and the cysts present may burst under pressure. For pain, RCOG suggests paracetamol or codeine within the maximum dose and advises avoiding anti-inflammatory drugs. When OHSS is severe, Cleveland Clinic describes hospitalization with IV fluids, fluid removal procedures, and blood thinners, and RCOG lists anti-sickness drugs, intravenous fluids, support stockings, and heparin injections. One nuance is activity: RCOG advises remaining active to reduce the risk of thrombosis, while University of Washington Medicine tells IVF patients to avoid high-impact activities like running or jumping because enlarged ovaries may twist. That kind of tension is exactly why self-treatment is a poor idea; the right plan comes from the treating clinic and a licensed physician.

What questions should intended parents ask their clinic about OHSS?

OHSS is one of the few IVF topics where preparation genuinely changes the experience, because the warning signs, the self-monitoring routine, and the escalation route can all be agreed before stimulation starts. The sources in this article show where the useful questions sit. The risk factor lists from Cleveland Clinic, University of Washington Medicine, and RCOG show that risk can be estimated from the medical history and from monitoring results, so it is fair to ask how one's own profile looks before the first injection. The prevention strategies described by ASRM and University of Washington Medicine, from trigger choice and cabergoline to freezing all embryos for a later transfer, show that cycles can be adjusted when risk rises, so it is worth asking in advance what would change and who decides. The concrete thresholds University of Washington Medicine gives its patients, daily weight and urine checks with clear call criteria, show the kind of practical instructions worth requesting in writing, including an after-hours contact route, which matters even more for anyone receiving treatment away from home. The questions below are starting points for that conversation. None of them replaces individual advice, and every decision about stimulation, triggering, freezing, and the response to symptoms belongs with the treating clinic and a licensed physician.

• Based on my follicle count, estradiol level, AMH, and history, am I considered at higher risk for OHSS in this cycle?
• Which trigger medication is planned, and would a leuprolide (Lupron) trigger or a lower HCG dose be appropriate in my case?
• Under what circumstances would you recommend freezing all embryos and delaying transfer to a later cycle?
• What exactly should I monitor after the trigger and retrieval, such as daily weight and urine output, and how should I report it?
• Which symptoms mean I should call during office hours, and which mean I need help right away, including outside office hours or while travelling?
• If OHSS develops, how would it be monitored and managed, and at what point would hospital care be considered?